PT - JOURNAL ARTICLE AU - Tzu-Chen Yen AU - Lai-Chu See AU - Ting-Chang Chang AU - Kuan-Gen Huang AU - Koon-Kwan Ng AU - Simon G. Tang AU - Yu-Chen Chang AU - Swei Hsueh AU - Chien-Sheng Tsai AU - Ji-Hong Hong AU - Cheng-Tao Lin AU - Angel Chao AU - Shih-Ya Ma AU - Wuu-Jyh Lin AU - Ying-Kai Fu AU - Chi-Chen Fan AU - Chyong-Huey Lai TI - Defining the Priority of Using <sup>18</sup>F-FDG PET for Recurrent Cervical Cancer DP - 2004 Oct 01 TA - Journal of Nuclear Medicine PG - 1632--1639 VI - 45 IP - 10 4099 - http://jnm.snmjournals.org/content/45/10/1632.short 4100 - http://jnm.snmjournals.org/content/45/10/1632.full SO - J Nucl Med2004 Oct 01; 45 AB - PET with 18F-FDG has shown its potential in cervical cancer. For maximizing the benefits of this new imaging technology, we aimed to define the prognostic features of recurrent cervical cancer patients for selecting appropriate candidates using 18F-FDG PET. Methods: Patients enrolled were from 2 independent prospective studies investigating the role of 18F-FDG PET in cervical cancer patients after definitive treatment with documented failure (CTRP-018) or unexplained elevated tumor marker serum levels (CTRP-016) and proven relapse after PET. A total of 55 eligible patients received PET and CT or MRI. Lesion status was determined from pathologic results or clinical follow-up. The benefits calculated were based on treatment that was modified because of the PET findings. The Cox proportional hazards ratio (HR) was used to select independent prognostic covariates. Results: Thirty-six (65.5%) patients had treatment that was modified due to PET. Primary radiation (HR = 14.62; 95% confidence interval [CI] = 2.74–77.92), squamous cell carcinoma antigen (SCC-Ag) ≥ 4 ng/mL (HR = 5.82; 95% CI = 1.53–22.04), and presence of symptoms (HR = 6.24; 95% CI = 1.99–19.61) at recurrence were significant factors associated with poor survival. A scoring system using these covariates defined 3 distinct prognostic groups: score ≤ 1 (HR = 1.00); score = 2 (HR = 6.91; 95% CI = 1.49–32.14); and score = 3 (HR = 60.46; 95% CI = 9.68–378.09) (P &lt; 0.0001). Conclusion: Using this risk score, 18F-FDG PET may offer maximal benefits by selecting appropriate recurrent cervical cancer patients for salvage therapy with precise restaging information.